Search
Agenus Inc
AGENAdd to Watchlist
3.490USD
+0.080+2.35%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
134.44MMarket Cap
1.69P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.35%
5 Days
+15.18%
1 Month
+2.80%
6 Months
+8.05%
Year to Date
+11.15%
1 Year
-42.50%
Key Figures
3.400Open
3.515High
680.58KVolume
1.69P/E TTM
LossP/E Dynamic
--Dividend TTM
1.77%Turnover Ratio
3.410Prev. Close
3.370Low
1.71MTurnover
LossP/E Static
-0.61P/B
0.00%Div Yield TTM
32.32%ROA
7.34052wk High
0.72Volume Ratio
-227.43MNet Profit
38.52MShares
2.0638EPS TTM
1.58Beta
-556.54%ROE
2.71052wk Low
4.25%Amplitude
100.00%Gross Margin
134.44MMarket Cap
0.09Reward/Risk
5.00%Risk Rate
TradingKey Stock Score of Agenus Inc
Currency: USD Updated: 2026-07-02Key Insights
Agenus Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 125 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Agenus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Agenus Inc Highlights
StrengthsRisks
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Overvalued
The company’s latest PE is 1.69, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.91M shares, decreasing 8.15% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 45.64K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
15.500
Target Price
+354.55%
Upside Space
Agenus Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Agenus Inc Info
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Ticker SymbolAGEN
CompanyAgenus Inc
CEOArmen (Garo H)
Websitehttps://agenusbio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Agenus Inc (AGEN)?
The current price of Agenus Inc (AGEN) is 3.49.
What is the symbol of Agenus Inc?
The ticker symbol of Agenus Inc is AGEN.
What is the 52-week high of Agenus Inc?
The 52-week high of Agenus Inc is 7.34.
What is the 52-week low of Agenus Inc?
The 52-week low of Agenus Inc is 2.71.
What is the market capitalization of Agenus Inc?
The market capitalization of Agenus Inc is 134.44M.
Is Agenus Inc (AGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Agenus Inc (AGEN) has an overall rating of Buy, with a price target of 15.50.
What is the Earnings Per Share (EPS TTM) of Agenus Inc (AGEN)?
The Earnings Per Share (EPS TTM) of Agenus Inc (AGEN) is -0.00.